Moderna Inc. (NASDAQ:MRNA) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET

Company Participants

Stéphane Bancel - Chief Executive Officer
Stephen Hoge - President
Jamey Mock - Chief Financial Officer
Lavina Talukdar - Senior Vice President, Investor Relations

Conference Call Participants

Salveen Richter - Goldman Sachs
Terence Flynn - Morgan Stanley
Michael Yee - Jefferies
Elliott Bosco - UBS
Gena Wang - Barclays
Luca Issi - RBC Capital
Alexandria Hammond - Bank of America
Edward Tenthoff - Piper Sandler
Jessica Fye - JP Morgan
Evan Wang - Guggenheim
Greg - TD Securities
Adi - Evercore ISI

Operator

Good day and thank you for standing by. Welcome to the Moderna second quarter 2024 conference call.

At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question and answer session. To ask a question during the session, you’ll need to press star-one-one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star-one-one again.

Please be advised today’s conference is being recorded.

I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead.

Lavina Talukdar

Thank you Kevin. Good morning everyone and thank you for joining us on today’s call to discuss Moderna’s second quarter 2024 financial results and business update.

You can access the press release issued this morning, as well as the slides that we will be reviewing, by going to the Investors section of our website.

On today’s call are Stéphane Bancel, our Chief Executive Officer; Jamey Mock, our Chief Financial Officer, and Stephen Hoge, our President.

Before we begin, please note that this conference call will include forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements.

I will now turn the call over to Stéphane.

Stéphane Bancel

Thank you Lavina. Good morning or good afternoon everyone. Thank you for joining us today. I will start with a review our business, Jamey will present our financial results for the quarter and take you through our basic financial framework. Stephen will then review our clinical progress. I will then close by sharing our commercial progress and our outlook for major upcoming milestones.